Scholarlink

Purpose <p>The aim of our study was to investigate the effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) treatment on the development of contrast induced nephropathy (CIN) in patients with heart failure with reduced ejection fraction (HFrEF) without diabetes mellitus (DM) undergoing elective coronary angiography (CAG) and percutaneous coronary intervention (PCI).</p> Methods <p>In this retrospective study after exclusion criteria, 390 patients (242 men, 148 women, mean age 63.7 ± 8.6&#xa0;years) were included. Patients were divided into two groups as with and without CIN and all parameters were compared and the parameters determining the patient group with CIN were found.</p> Results <p>CIN occurred in 76 (19.5%) of 390 patients. Age (<i>p</i> = &lt; 0.001), smoking (<i>p</i> = 0.015), total procedure time (<i>p</i> = 0.018), contrast volume (<i>p</i> = &lt; 0.001) and PCI (<i>p</i> = 0.030) were significantly higher and left ventricular ejection fraction (LVEF) (<i>p</i> = &lt; 0.001) and SGLT2i use were lower (<i>p</i> = 001) in the CIN group. In the logistic regression analysis, it was found that advanced age (OR = 1.215, %95CI-1.144‒1.290, <i>p</i> &lt; 0.001), low LVEF (OR = 0.858, %95 CI-0.807‒0.912, <i>p</i> &lt; 0.001), increased contrast volume (OR = 1.030, %95 CI-1.016‒1.044, <i>p</i> &lt; 0.001) and not using SGLT2i treatment (OR = 0.269, %95 CI-0.163‒0.454, <i>p</i> &lt; 0.001) were found to independently determine the risk of CIN.</p> Conclusion <p>In conclusion, SGLT2i treatment significantly reduced the development of CIN in HFrEF patients without DM. Our findings need to be supported by multicenter prospective randomized controlled trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sodium-Glucose Cotransporter 2 Inhibitors Decrease Contrast Induced Nephropathy In Patients With Heart Failure With Reduced Ejection Fraction Without Diabetes Mellitus

  • 期刊论文

  • 发表日期：

    2025年9月22日

查看全文
  • Fadime Koca,
  • Mustafa Lutfullah Ardic,
  • Hazar Harbalioglu,
  • Abdullah Eren Çetin,
  • Bercem Berent Kaya,
  • Mehmet Can Erisen,
  • Hilmi Erdem Sumbul,
  • Hasan Koca,
  • Mevlut Koc

摘要

Purpose

The aim of our study was to investigate the effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) treatment on the development of contrast induced nephropathy (CIN) in patients with heart failure with reduced ejection fraction (HFrEF) without diabetes mellitus (DM) undergoing elective coronary angiography (CAG) and percutaneous coronary intervention (PCI).

Methods

In this retrospective study after exclusion criteria, 390 patients (242 men, 148 women, mean age 63.7 ± 8.6 years) were included. Patients were divided into two groups as with and without CIN and all parameters were compared and the parameters determining the patient group with CIN were found.

Results

CIN occurred in 76 (19.5%) of 390 patients. Age (p = < 0.001), smoking (p = 0.015), total procedure time (p = 0.018), contrast volume (p = < 0.001) and PCI (p = 0.030) were significantly higher and left ventricular ejection fraction (LVEF) (p = < 0.001) and SGLT2i use were lower (p = 001) in the CIN group. In the logistic regression analysis, it was found that advanced age (OR = 1.215, %95CI-1.144‒1.290, p < 0.001), low LVEF (OR = 0.858, %95 CI-0.807‒0.912, p < 0.001), increased contrast volume (OR = 1.030, %95 CI-1.016‒1.044, p < 0.001) and not using SGLT2i treatment (OR = 0.269, %95 CI-0.163‒0.454, p < 0.001) were found to independently determine the risk of CIN.

Conclusion

In conclusion, SGLT2i treatment significantly reduced the development of CIN in HFrEF patients without DM. Our findings need to be supported by multicenter prospective randomized controlled trials.